.png)
.png)
BioIVT highlights ADME-Tox research advances at ISSX/MDO 2022
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
“We are looking forward to meeting with the research community at ISSX,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “The ISSX conference is an important event in our year, providing an opportunity for us to talk to our customers in person, learn more about their research objectives and challenges, and let them know how BioIVT is growing and adapting to support them. As illustrated by our recent acquisition of Cypex and its recombinant enzyme products, we are continuing to expand our extensive portfolio of hepatic products and ADME-Tox research services.”
“We are also excited to announce that Dr. Thomas Kralj has joined the BioIVT research team as a study director,” said Dr. Kenneth Brouwer, Vice President of Technology, ADME-Tox and Research & Development. “We have been collaborating with Tom for several years on his research into improving in vitro models of nonalcoholic steatohepatitis (NASH) and cholestatic hepatotoxicity at Monash University in Melbourne, Australia. I am sure that our customers will appreciate having the opportunity to work with Tom when designing and implementing their research programs.”
ISSX Research Focus
As the leading global provider of hepatocytes, BioIVT is hosting an industry-sponsored symposium entitled “The Role of Liver-humanized Mice in the Drug Development Toolkit.” During this presentation, Sean Nygaard, Operations Manager at Yecuris Corporation, will discuss how liver-humanized mice have proven invaluable for metabolic and toxicity studies, testing liver-targeted gene therapies, analyzing gene regulation, and modeling hepatotropic infections. His presentation will take place from 7:15-8:15 a.m. on September 13 in Grand Ballroom 3.
Dr. Kralj will present research he conducted with colleagues at Monash University, the University of North Carolina, and BioIVT in the poster entitled “Effect of Drugs That Cause Cholestatic Drug-Induced Liver Injury on Bile Acid Transport and Metabolism” (P92). Their work provides evidence of the adaptive response of hepatocytes to bile acid transport impairment and demonstrates further how BioIVT’s C-DILI™ Assay can successfully predict the risk of cholestatic hepatotoxicity. The C-DILI Assay has proven effective because it incorporates complex regulatory, transport and metabolic responses.
Fellow BioIVT study director Dr. Mark Warren will present the poster entitled “Drug-Drug Interaction Potential of Pharmaceutical Excipients on Uptake and Efflux Transporters” (P193). This research, which was sponsored by the Bill and Melinda Gates Foundation, demonstrates that excipients in oral drugs, such as coloring agents, fillers, stabilizers, and preservatives, can inhibit transporters in the gastrointestinal tract. As a result, these ingredients may have pharmacokinetic effects, such as blocking or reducing drug uptake.
BioIVT researchers also collaborated with academic and industry colleagues to co-author two other posters: “Ontogeny of Human Aldehyde Oxidase” (A11) and “Proteomic Characterization of Clinically Relevant Drug-metabolizing Enzymes and Transporters in the Liver and Different Intestinal Sections of Sprague Dawley Rat for Applications in PBPK Modeling” (P166).
BioIVT experts will be available to answer questions about the company’s research services and its extensive collections of high-quality hepatocytes, hepatic non-parenchymal cells, and subcellular fractions for in vitro ADME-Tox models in booth #35.
Additional information about ISSX/MDO 2022
“We are looking forward to meeting with the research community at ISSX,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “The ISSX conference is an important event in our year, providing an opportunity for us to talk to our customers in person, learn more about their research objectives and challenges, and let them know how BioIVT is growing and adapting to support them. As illustrated by our recent acquisition of Cypex and its recombinant enzyme products, we are continuing to expand our extensive portfolio of hepatic products and ADME-Tox research services.”
“We are also excited to announce that Dr. Thomas Kralj has joined the BioIVT research team as a study director,” said Dr. Kenneth Brouwer, Vice President of Technology, ADME-Tox and Research & Development. “We have been collaborating with Tom for several years on his research into improving in vitro models of nonalcoholic steatohepatitis (NASH) and cholestatic hepatotoxicity at Monash University in Melbourne, Australia. I am sure that our customers will appreciate having the opportunity to work with Tom when designing and implementing their research programs.”
ISSX Research Focus
As the leading global provider of hepatocytes, BioIVT is hosting an industry-sponsored symposium entitled “The Role of Liver-humanized Mice in the Drug Development Toolkit.” During this presentation, Sean Nygaard, Operations Manager at Yecuris Corporation, will discuss how liver-humanized mice have proven invaluable for metabolic and toxicity studies, testing liver-targeted gene therapies, analyzing gene regulation, and modeling hepatotropic infections. His presentation will take place from 7:15-8:15 a.m. on September 13 in Grand Ballroom 3.
Dr. Kralj will present research he conducted with colleagues at Monash University, the University of North Carolina, and BioIVT in the poster entitled “Effect of Drugs That Cause Cholestatic Drug-Induced Liver Injury on Bile Acid Transport and Metabolism” (P92). Their work provides evidence of the adaptive response of hepatocytes to bile acid transport impairment and demonstrates further how BioIVT’s C-DILI™ Assay can successfully predict the risk of cholestatic hepatotoxicity. The C-DILI Assay has proven effective because it incorporates complex regulatory, transport and metabolic responses.
Fellow BioIVT study director Dr. Mark Warren will present the poster entitled “Drug-Drug Interaction Potential of Pharmaceutical Excipients on Uptake and Efflux Transporters” (P193). This research, which was sponsored by the Bill and Melinda Gates Foundation, demonstrates that excipients in oral drugs, such as coloring agents, fillers, stabilizers, and preservatives, can inhibit transporters in the gastrointestinal tract. As a result, these ingredients may have pharmacokinetic effects, such as blocking or reducing drug uptake.
BioIVT researchers also collaborated with academic and industry colleagues to co-author two other posters: “Ontogeny of Human Aldehyde Oxidase” (A11) and “Proteomic Characterization of Clinically Relevant Drug-metabolizing Enzymes and Transporters in the Liver and Different Intestinal Sections of Sprague Dawley Rat for Applications in PBPK Modeling” (P166).
BioIVT experts will be available to answer questions about the company’s research services and its extensive collections of high-quality hepatocytes, hepatic non-parenchymal cells, and subcellular fractions for in vitro ADME-Tox models in booth #35.
Additional information about ISSX/MDO 2022